Ongoing Trials
The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy: This is a randomized controlled trial looking at the effect of sulodexide on the progression of diabetic nephropathy.

Completed Trials and Studies
Aminoguanidine in Diabetic Nephropathy: A double blind randomized placebo trial with aminoguanidine, an advanced glycosylation end product blocker, in Type I diabetics found less proteinuria and retinopathy but was short of statistical significance in preventing doubling of the serum creatinine. (Bolton K., Appel GB, et al for the ACTION I Investigator Group- Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol.Jan-Feb;24(1):32-40.  2004)

Losartan in Diabetic Nephropathy: The RENAAL trial sponsored by Merck Pharmaceutical Corp. evaluated over 1500 type II diabetics with decreased renal function and proteinuria randomized to either losartan an angiotensin II receptor blocker, or other antihypertensives over a four year period. The study showed a major reduction in proteinuria, renal failure, and renal failure and death in the AII blocker receptor group:

1. Brenner BM, Cooper ME, DeZeuw D, et al. (Appel GB - investigators). Effects of Losartan in Renal and Cardiovasscular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Eng J Med. 345: 861-869, 2001. 

2. Appel GB, Radhakrishnan J, et al. RENAAL Study.
Analysis of metabolic parameters as predictors of risk in the RENAAL study.Diabetes Care. May;26(5):1402-7.2003

Other recent abstracts and publications of Glomerular Center Members:
Appel GB, Appel AS.Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis. Sep-Oct;47(2):105 2004

Nasr SH, Markowitz GS, Stokes MB, Seshan SV, Valderrama E, Appel GB, Aucouturier P, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. Jan;65(1):85-96.2004 

Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD.  Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int. Apr;63(4):1450-61 2003. 

Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD. 
 Renal monoclonal immunoglobulin deposition disease: the disease spectrum.
J Am Soc Nephrol.  Jul;12(7):1482-92. 2001 

Matalon A, Radhakrishnan J, Appel GB, Valeri A. HIV and the Kidney: Management Challenges. Resident and Staff Physician 47:44-50, 2000.

Appel Gerald B. Guest Editor Treatment of Glomerular Diseases Seminars in Nephrology Vol. 20 Introduction pp 231- 233 May 2000.

Cheng J-T, Anderson H, Markowitz GS, Appel GB, Pogue V, D'Agati V. Hepatitis C Virus Associated Glomerular Disease in Patients with HIV Co-infection. JASN 10:1566-1574,1999. 

Kambham N, Markowitz GS, Appel GB, Aucouturier P, D'Agati V. Heavy Chain Disease: The Disease Spectrum. AJKD 33:954-962,1999. 

Matalon A. Valeri A, Appel GB. How to evaluate and treat patients with HIV associated nephropathy. J Critical Illness 15: 658-674,2000. 

Joseph R, Radhakrishnan J, Appel GB. Anticardiplipin Antibodies and Renal Disease. Curr Opinion in Hypertension and Nephrol.10: 175-181, 2001. 

Halevy D, Radhakrishnan J, Markowitz G, Appel GB. Thrombotic Microangiopathies. in " Renal Issues in Critical Care " for Critical Care Clinics guest editor Laura Dember . (18: 309-321 2002) 

Halevy D, Radhakrishnan J, Appel GB. Racial and Socioeconomic Factors in glomerular Diseases. Sem. In Nephrology. 21: 403-411, 2001. 

Appel GB. COX 2 Inhibitors and the Kidney. Clin. and Exper. Rheumatology 19: Suppl 25: S37-S40, 2001